Immunoassays

The sensitive, reproducible and high-throughput nature of immunoassays make them especially well-suited to characterize immunogenicity, neutralization and pharmacodynamic responses of candidate biologics. Pre-existing immunity, cross- reactivity and non-specific binding can be identified during screening while longitudinal monitoring allows innovators to observe the modulatory effects of their treatment regime along with possible inactivation of the intended therapeutic effect While colorimetric ELISAs are essential for many programs, detection technologies such as magnetic beads, biolayer interferometry, electrochemiluminescence and fluorescence have provided the means to extend the dynamic range of an assay, limit matrix interference and to multiplex anywhere from 2 to 100 analytes. Advantages range from sample conservation to increased precision, reproducibility and data capacity, aiding developers across all stages of the product development pathway. Applications of immunoassays: • Candidate screening • Preclinical development • Dose determination • Mechanism of action • Monoclonal antibody characterization • Immunogenicity of biologic therapies • Vaccine immunogenicity ABL’s decades of experience in antigen & antibody binding assays include: • ELISA- Quantitative, Semi-quantitative or Qualitative • Electrochemiluminescent (ECL) Multiplex Analysis • Anti-Drug Antibody Assays (ADA) • Binding Affinity • Epitope Binning • Antibody Isotyping ABL's immunoassay authorities can provide: • Support for preclinical and clinical testing plus product characterization • A variety of techniques and state-of-the-art instrumentation to fit any need • Flexible options ranging from cost efficient, colorimetric assays to multiplex and ultra-sensitive upgrades • Custom assay development, commercial kit optimization and method validation